Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pancreatic enzyme replacement therapy for pancreatic exocrine insufficiency in unresectable pancreatic cancer
2023-507367-18-00Phase 4Authorised
- Sponsor
- Instituto de Investigación Sanitaria de Santiago de Compostela
- Start
- Aug 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 4
01
Overview
Phase 4, randomised, open-label trial of pancrelipase in exocrine pancreatic insufficiency (EPI) (2 arms), sponsored by Instituto de Investigación Sanitaria de Santiago de Compostela. Primary endpoint: Change in body weight. Planned start Aug 2023; status: authorised.
02
Drugs
pancrelipase
03
Conditions
exocrine pancreatic insufficiency (EPI)
Beyond the preview
Go deeper on 2023-507367-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507367-18-00.